Panretin (Pan-RET-in, alitretinoin) gel, the first TOPICAL treatment for Kaposi's sarcoma

April 1999

The FDA just approved Panretin (Pan-RET-in, alitretinoin) gel, the first TOPICAL treatment for Kaposi's sarcoma.

Alitretinoin is a form of retinoic acid.

It's applied to skin lesions to inhibit cell growth...it doesn't prevent new lesions or treat systemic disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new SYNTHETIC conjugated estrogens tablet called Cenestin
Diabetes restrict the use of Rezulin (troglitazone) for diabetes
Interactions new cytochrome P450 drug interactions
Cardiology whether aspirin reduces the efficacy of ACE inhibitors
Cardiology Drinking tea might reduce the risk of MI
Dermatology Lamisil (terbinafine) CREAM will soon switch from Rx to OTC
Infectious Diseases stronger warning not to use Rebetron during pregnancy
Infectious Diseases metformin (Glucophage) to treat some of the metabolic complications of HIV treatment
Infectious Diseases Panretin (Pan-RET-in, alitretinoin) gel, the first TOPICAL treatment for Kaposi's sarcoma
Effexor XR (venlafaxine) for generalized anxiety disorder
best treatment to help people stop smoking
Women's Health Viagra (sildenafil) is effective for WOMEN
Women's Health new OTC monitor called the ClearPlan Easy Fertility Monitor
Thyroid Disorders some patients feel better when they're given BOTH levothyroxine (T4) AND triiodothyronine (T3)
lots of hype in the news about Cellasene
NADH (Enada), an OTC supplement that's being promoted for chronic fatigue syndrome
Gastroenterology High-dose ranitidine (Zantac) usually ISN'T more effective
Gastroenterology Two new proton pump inhibitors will soon hit the market
Interactions Cytochrome P450